Regeneron Pharmaceuticals Receives “Buy” Rating from BMO Capital Markets (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reaffirmed by analysts at BMO Capital Markets in a research report issued to clients and investors on Tuesday, Analyst Ratings Network.com reports. They currently have a $325.00 price target on the stock, up from their previous price target of $294.00. BMO Capital Markets’ price target points to a potential upside of 6.33% from the company’s current price.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 305.65 on Tuesday. Regeneron Pharmaceuticals has a one year low of $136.13 and a one year high of $311.00. The stock has a 50-day moving average of $265.3 and a 200-day moving average of $240.4. The company has a market cap of $29.862 billion and a price-to-earnings ratio of 40.41.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.73 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter in the prior year, the company posted $0.90 earnings per share. The company’s quarterly revenue was up 50.5% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $3.50 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 145,356 shares of the stock on the open market in a transaction dated Thursday, September 19th. The stock was sold at an average price of $302.86, for a total value of $44,022,518.16. Following the sale, the chairman now directly owns 65,759 shares of the company’s stock, valued at approximately $19,915,771. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $298.00 to $329.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Monday, September 16th. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $286.00 to $293.00 in a research note to investors on Friday, September 13th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $267.53.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.